Neuromuscular drug pipelines

Takeda

TAK-831

cerebellar ataxia, schizophrenia

D- amino acid oxidase (DAAO) inhibitor

Phase I


Takeda

Rasagiline

Parkinson's disease

Monoamine oxidase B (MAO-B) inhibitor

Phase III


Roche

Olesoxime

spinal muscular atrophy

Phase II


Otsuka

TAS-205

Duchenne Muscular Dystrophy

PGD synthase-inhibitor

Phase I


Novartis

bimagrumab

Sporadic inclusion body myositis

Inhibitor of activin type II receptor

Phase III


Biogen

BIIB065

myotonic dystrophy

DMPK gene inhibition

Phase I


Biogen

Nusinersen

spinal muscular atrophy

Phase III


Roche

RG7800

spinal muscular atrophy

SMN2 splicing modifier

Phase I


Roche

RG7916

spinal muscular atrophy

SMN2 splicing modifier

Phase I


Shire

SHP611: MLD

CNS / Neuromuscular

Enzyme

Phase II


GlaxoSmithKline

Benlysta (belimumab)

myaesthenia gravis

B lymphocyte stimulator monoclonal antibody (i.v.)

Phase II